Cyclo Therapeutics (CYTH) Stock Price, News & Analysis

Company Overview

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Key Stats

• Today's Range: $0.72 to $0.72
• 50-Day Range: $0.65 to $1.19
• 52-Week Range: $0.55 to $1.62
• Volume: N/A
• Average Volume: 426,491 shs
• Market Capitalization: $23.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.95
• Consensus Rating: Hold

Cyclo Therapeutics Stock Analysis - MarketRank™

Cyclo Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 474th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cyclo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cyclo Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Cyclo Therapeutics are expected to remain at ($0.66) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclo Therapeutics has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.55% of the float of Cyclo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclo Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclo Therapeutics has recently decreased by 19.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclo Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.55% of the float of Cyclo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclo Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclo Therapeutics has recently decreased by 19.55%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.55% of the stock of Cyclo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CYTH Stock Analysis - Frequently Asked Questions

How have CYTH shares performed this year?

Cyclo Therapeutics' stock was trading at $0.59 at the start of the year. Since then, CYTH shares have increased by 22.1% and is now trading at $0.7206.
View the best growth stocks for 2025 here.

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) issued its earnings results on Thursday, August, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.07. The firm earned $0.12 million during the quarter, compared to analyst estimates of $0.40 million.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclo Therapeutics investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Ford Motor (F), Alphabet (GOOG), Cassava Sciences (SAVA), Zoom Video Communications (ZM) and Fisker (FSR).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 4/16/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTH
• CIK: 922247
• Web: www.ctd-holdings.com
• Phone: (386) 418-8060
• Fax: 321-244-8351
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $0.95
• High Stock Price Target: $0.95
• Low Stock Price Target: $0.95
• Potential Upside/Downside: +31.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,060,000.00
• Net Margins: -2,847.19%
• Pretax Margin: -2,847.30%
• Return on Equity: N/A
• Return on Assets: -307.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: $870,725.00
• Price / Sales: 27.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 3.43

Miscellaneous

• Outstanding Shares: 32,919,000
• Free Float: 23,116,000
• Market Cap: $23.72 million
• Optionable: No Data
• Beta: -0.57